Progress in the research on multi-target-directed drugs against Alzheimer's disease

Yaoxue Xuebao

Volumn 44, Issue 3, 2009, Pages 258-263

  Liu, Rui Ting ^b   Lu, Qiu Jun ^a  

^a Genova Beijing Biopharmaceutical Research Institute   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Multi target directed; Selective estrogen receptor modulators

Indexed keywords

SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ALZHEIMER DISEASE; MEDICAL RESEARCH; REVIEW;

ALZHEIMER DISEASE; ANIMALS; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; DRUGS, CHINESE HERBAL; HUMANS; INDANS; INDOLES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TACRINE; THIOCTIC ACID;

EID: 67249156779     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Opar A. Mixed results for disease-modification strategies for Alzheimer's disease [J]. Nat Rev Drug Discov, 2008, 7: 717-718.
2. Melnikova I. Therapies for Alzheimer's disease [J]. Nat Rev Drug Discov, 2007, 6: 34 1-342.
3. Agoston V, Csermely P, Pongor S. Multiple weak hits confuse complex systems: A transcriptional regulatory network as an example [J], Phys Rev E Stat Nonlin Soft Matter Phys, 2005,71(5 Pt 1): 051909.
4. Csermely P. Strong links are important, but weak links stabilize them [J]. Trends Biochem Sci, 2004, 29: 33 1-334.
5. Fink DM, Palermo MG, Bores GM, et al. Imino 1, 2, 3, 4- tetrahydrocyclopent [b] indole carbamates as dual inhibitors of acetylcholinesterase and monoamine oxidase [J]. Bioorg Med Chem Lett, 1996, 6: 625-630.
6. Sterling J, Herzig Y, Goren T, et al. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer' s disease [J]. J Med Chem, 2002, 45: 5260-5279.
7. Ronchetti D, Impagnatiello F, Guzzetta M, et al. Modulation of iNOS expression by a nitric oxide-releasing derivative of the natural antioxidant ferulic acid in activated RAW 264.7 macrophages [J]. Eur J Pharmacol, 2006, 532: 162-169.
8. Rodriguez-franco MI, Fernandez-bachiller MI, Perez C, et al. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties [J]. J Med Chem, 2006, 49: 459-462.
9. Fisher A. M1 muscarinic agonists target major hallmarks of Alzheimer' s disease - the pivotal role of brain Ml receptors [J]. Neurodegener Dis, 2008, 5: 237-240.
10. Li L, Sengupta A, Haque N, et al. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration [J]. FEBS Lea, 2004, 566: 261-269.
11. Doody RS, Gavrilova SI, Sano M, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer' s disease: A randomised, double-blind, placebo-controlled study [J]. Lancet, 2008, 372: 207-215.
12. Rosini M, Andrisano V, Bartolini M, et al. Rational approach to discover multipotent anti-Alzheimer drugs [J]. J Med Chem, 2005,48: 360-363.
13. Youdim MBH, Fridkin M, Zheng HL. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases [J]. Mech Ageing Dev, 2005, 126: 317-326.
14. Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces arnyloid in vivo [J]. J Biol Chem, 2005, 280: 5892-590l.
15. Zhang HY, Tang XC. Neuroprotective effects of huperzine A: New therapeutic targets fomeurodegenerative disease [J]. Trends Pharmacol Sci, 2006, 27: 619-625.
16. Li L, Thang L, Thao L, et al. 2008 Beijing Symposium on Aging and Neurodegeneration [C]. Beijing: Chinese Academy of Medical Sciences, 2008: 17.
17. Brinton RD. Investigative models for determining hormone therapy-induced outcomes in brain: Evidence in support of a healthy cell bias of estrogen action [J]. Ann N Y Acad Sci, 2005, 1052: 57-74.
18. Brann DW, Dhandapani K, Walcade C, et al. Neurotrophic and neuroprotective actions of estrogen: Basic mechanisms and clinical implications [J]. Steroids, 2007, 72: 381-405.
19. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer [J]. Lancet, 1997, 350: 1047-1059.
20. Beresford SA, Weiss NS, Voigt LF, Ct al. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women [J]. Lancet, 1997, 349: 458-461.
21. Ravnikar VA. Compliance with hormone replacement therapy: Are women receiving the full impact of hormone replacement therapy preventive heath benefits? [J]. Women Health Issues, 1992, 2: 75-80.
22. Brinton RD. Requirements of a brain selective estrogen: Advances and remaining challenges for developing a NeuroSERM [J]. JAlzheimers Dis, 2004,6: S27-35.
23. O'Neill K, Chen SH, Bnnton RD. Impact of the selective estrogen receptor modulator, tamoxifen, on neuronal outgrowth and survival following toxic insults associated with aging and Alzheimer's disease [J]. Exp Neurol, 2004, 188: 268-278.
24. O'Neill K, Chen SH, Brinton RD. Impact of the selective estrogen receptor modulator, raloxifene, on neuronal survival and outgrowth following toxic insults associated with aging and Alzheirner's disease [J]. Exp Neurol, 2004, 185: 63-80.
25. Zhao LQ, O'Neill K, Brinton RD. Estrogenic agonist activity of ICI 182780 (Faslodex) in hippocampal neurons: Implications for basic science under-standing of estrogen signaling and development of estrogen modulators with a dual therapeutic profile [J]. J Pharmacol Exp Ther, 2006, 319: 1124-1132.
26. Yaffe KK, Krueger 5, Sarkar D, et al. Cognitive function in postmenopausal women treated with raloxifene [J]. N Engl J Med, 2001, 344: 1207-1213.
27. Weiser Mi, Foradori CD, Handa RJ. Estrogen receptor beta in the brain: From form to function [J]. Brain Res Rev, 2008, 57: 309-320.
28. An SJ. The study of the relationship between hippocampal ERs gene expression and brain degeneration and learning and memory function [D]. Beijing: Academy of Military Medical Science, 2002.
29. Jarvinen TA, Pelto-Huildco M, Hoffi K, et al. Estrogen receptor beta is coexpressed with ERa and PR and associated with nodal status, grade, and proliferation rate in breast cancer [J]. Am J Pathol, 2000, 156: 29-35.
30. Carroll JC, Pike CJ. Selective estrogen receptor modulators differentially regulate Alzheimer-like changes in female 3xTg-AD mice [J]. Endocrinology, 2008, 149: 2607-2611.
31. Escande A, Pillon A, Balaguer P. et al. Evaluation of ligand selectivity using reporter cell lines stably expressing estrogen receptor alpha or beta [J]. Biochem Pharmacol, 2006, 71: 1459-1469.
32. Zhao LX, Chen Q, Brinton RD. Neuroprotective and neurotrophic efficacy of phytoestrogens in cultured hippocampal neurons [J]. Exp Biol Med, 2002, 227: 509-519.
33. Bang OY, Hong HS, Kim DH, et al. Neuroprotective effect of genistein against beta amyloid-induced neurotoxicity [J]. Neurobiol Dis, 2004, 16: 21-28.
34. Sun Z, Lu QJ, Wen LQ, et al. Establishment and its application of a reportor-based screening model for discovering new ligands of estrogen receptor α subtypes [J]. Acta Pharm Sin (Japanese Source)2000, 35: 747-751.
35. Chen LM, Lu QJ, Wen LQ, et al. Establishment of a reportor gene-based cell screening model for discovering new agonists of estrogen receptor β subtype [J]. Ada Phana Sin (Japanese Source) 2006,41: 721-726.
36. Tu PH. Pu XP, Shang WF, et al. New pharmaceutical usage of echinacoside (Japanese Source): CN, 200510002898 [P]. 2006-08-02.
37. Liu RT, Bian GX, Zou LB, et al. Neuroprotective effects of liquiritin and its inhibitory actions on cholinesterase acitivity [J]. Chin New Drugs J (Japanese Source)2008, 17: 41-44.
38. Yang Y, Bian GX, Lu QJ. Neuroprotection and neurotrophism effects of liquiritin on primary cultured hippocampal cells [J]. ChinaJ Chin Mater Med (Japanese Source)2008, 33: 931-935.
39. Mersereau JE, Levy N, Staub RE, et al. Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist [J]. Mol Ccl Endocrinol, 2008, 283: 49-57.
40. ΚB- dependent iNOS and proinflammatory cytokines production [J]. Br J Pharinacol, 2008, 154: 165-173.
41. Flight MH. Neurodegenerative disease: new ways of tackling Aβ toxicity [J]. Nat Rev Drug Discov, 2008, 7: 889.